Tag Archive for: Albert Bourla

“Pfizer’s position is that we believe that obesity is a place that we have the ability to play and win. So we will have to play,” Bourla told reporters ahead of his presentation at the JPMorgan healthcare conference in San Francisco.

“It is not negotiation at all. It is price setting,” Chief Executive Albert Bourla said at a Reuters newsmaker event on Thursday, referring to the Biden Administration’s signature drug pricing reform, part of the Inflation Reduction Act (IRA).

Biopharma rallies behind FDA after Texas abortion pill ruling Published: Apr 11, 2023 By Tristan Manalac BioSpace In an open letter published Monday, more than 480 biopharma industry leaders, including […]

The U.S. government on Monday appealed a Texas judge’s decision to suspend the Food and Drug Administration’s 23-year-old approval of a key abortion drug, saying the ruling endangered women’s health by blocking access to a pill long deemed safe.

Pfizer Inc. on Tuesday forecast a bigger-than-expected drop in sales of its COVID-19 vaccine and treatment in 2023, intensifying investor concerns over demand for the products as governments cut orders and work through inventories.

Pfizer forecasted stable growth in the coming years, driven by a strong product push to cushion its non-COVID business and exclusivity losses, according to company chairman and Chief Executive Officer Albert Bourla, M.D., Monday.

Pfizer Inc. is not in talks with Chinese authorities to license a generic version of its COVID-19 treatment Paxlovid for use there, but is in discussions about a price for the branded product, Chief Executive Albert Bourla said on Monday.

Company CEO Albert Bourla has received four doses of the COVID vaccine developed by Pfizer and its German partner BioNTech but said he has not yet taken the new bivalent booster.

Pfizer Inc. Chief Executive Officer Albert Bourla said on Monday he had tested positive for COVID-19 and was experiencing very mild symptoms.

COVID-19 vaccines that specifically target the Omicron and other variants are under development, Pfizer Inc.’s chief executive said on Wednesday, adding that the company will be able to quickly adapt shots as the novel coronavirus mutates.